IRCT20210808052110N1
Recruiting
Phase 2
To evaluate Neoadjuvant chemotherapy followed by chemoradiation in patients with unresectable cervical cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shiraz University of Medical Sciences
- Enrollment
- 74
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Unresectable cervical cancer(IIB toIVA,IB3,IIAmore than 4cm)
- •2\.No history of metastasis
- •3\.Adequate renal function(GFR more than 60ml per min per1\.73\)
- •4\.Adequate hepatic function(Liver enzyme\<5\* upper limit normal)
- •5\.Adequate bone marrow function(Absolute neutrophil\>1500\)
- •6\-Without history of systemic disease
- •7\.Absence of active infection
- •8\.Absence of previous or concurrent oncology pathology
- •9\.ECOG performance status 0 and 1
- •10\.Age 18 to 75 years
Exclusion Criteria
- •1\-Previous pelvic radiation
- •2\-Pregnancy
- •3\-Serious medical illness
- •4\-Hypersensitivity to chemotherapy agent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prospective study of neoadjuvant chemotherapy for HER2 positive breast cancer.JPRN-UMIN000046338Sapporo Medical University24
Recruiting
Not Applicable
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancerBreast cancerJPRN-UMIN000029433Tokyo medical university70
Completed
Not Applicable
Effect of neoadjuvant chemotherapy in patients with gastric cancerIRCT2015020220906N1Vice chancellor for Research and Technology30
Recruiting
Phase 3
A Phase III Trial to Investigate the Effect of NACT in Lymph Node Positive Cervix CancerHealth Condition 1: C539- Malignant neoplasm of cervix uteri, unspecifiedCTRI/2023/08/056902Dr. Partha Sarathi Bhattacharyya
Recruiting
Not Applicable
A phase II study of Neoadjuvant chemotherapy plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage ovarian cancer (TRU-D)NeoplasmsKCT0003742Yonsei University Health System, Severance Hospital24